Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Dosage forms and strengths
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Product description Product information

Dosage forms and strengths

1 evidence topic · 1 source

Investigational tablet formulations

“Bezuclastinib Tablets (Formulation A)” (opens the source at this quote in a new tab)
“Bezuclastinib Tablets (Formulation B)” (opens the source at this quote in a new tab)

Marketed dosage strengths

Not applicable.

Cogent clinical drug-product safety data sheet

No evidence found.